Transarterial Radioembolization (TARE) Agents beyond ⁹⁰Y-Microspheres

Area of Science:

• Hepatobiliary oncology
• Interventional radiology
• Nuclear medicine

Background:

• Liver malignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma, are leading causes of cancer death with rising incidence.
• HCC often has a poor prognosis due to underlying liver disease and late diagnosis, limiting curative surgical options to 20-30% of patients.
• Internal radionuclide therapy, specifically transarterial radioembolization (TARE), presents an attractive treatment for intermediate to advanced liver tumors.

Purpose of the Study:

• To review alternative transarterial radioembolization (TARE) technologies currently under development and investigation in clinical trials.
• To focus on novel TARE approaches for treating hepatocellular carcinoma (HCC).

Main Methods:

• Review of current clinical trial data on emerging TARE technologies.
• Analysis of alternative radiolabeled embolizing agents and delivery systems.
• Comparative assessment of novel TARE approaches against established methods.

Main Results:

• Established TARE using ⁹⁰Y-loaded microspheres shows promising outcomes but faces limitations due to high cost and limited availability.
• Several alternative TARE technologies are in development, aiming to improve accessibility and potentially efficacy.
• Ongoing clinical trials are evaluating the safety and effectiveness of these novel TARE approaches for liver tumors, particularly HCC.

Conclusions:

• While ⁹⁰Y-TARE is an established treatment, its cost and availability restrict widespread use.
• Development of alternative TARE technologies is crucial to expand treatment options for patients with liver malignancies, especially HCC.
• Further research and clinical trials are needed to validate the efficacy and cost-effectiveness of these emerging TARE alternatives.